← board
IMDX
distress 4/10 · elevated risk$5.01+0%today-41% from 52w high
Lead: transplant rejection
Revenue
pre-revenue
Liquidity
$28M
Runway
1.2 yrs
Shares 1y
+13%
Price & events
-25.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
+6.4%
1W
-6.7%
1M
+42.3%
3M
-23.2%
6M
+66.4%
1Y
+54.9%
2Y
-95.4%
5Y
-89.5%
All
Overview
- Market Cap
- $161.77M
- Volume
- 4.49K
- 52 Week Range
- $2.40 – $8.48
- Total Shares
- 32.29M
- Float Shares
- 10.00M
- Short %
- 6.36%
- % Held by Insiders
- 21.28%
- % Held by Institutions
- 60.78%
- RVOL
- 0.02x
- Beta
- 1.76
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- June 29 – July 2, 2025conferencedata presentationsecondaryGraftAssureIQ · Exhibiting at European Society for Organ Transplantation (ESOT) Congress in London.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $8 (+66% upside) · 3 analysts
- 2026-02-17Lake StreetBuy
- 2025-11-11NeedhamBuy
- 2025-08-18NeedhamBuy
- 2025-05-21Lake StreetBuy
- 2025-05-13NeedhamBuy
- 2025-04-08NeedhamBuy
Competitors — transplant rejection
Recent news
- 2026-07-23Insight Molecular Diagnostics (IMDX) Showcases Promising Study o - GuruFocus
- 2026-07-23iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication - GlobeNewswire
- 2026-07-20Enterprise value to revenue forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
- 2026-07-17Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio - Sahm
- 2026-07-16Insight Molecular Diagnostics Inc. Announces Favorable Medicare Coverage Decision Supporting Commercial Adoption Of GraftAssure Assay Portfolio - marketscreener.com
- 2026-07-16Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio - GlobeNewswire
- 2026-07-05If You Invested $1,000 in Insight Molecular Diagnostics Inc. (IMDX) - Stock Titan
- 2026-06-29IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.